MetaCap

ABVC BioPharma (ABVC) vs Incannex Healthcare (IXHL)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

ABVC BioPharma (ABVC) has outperformed Incannex Healthcare (IXHL) over the past year, losing 67.8% versus a loss of 80.3%. ABVC BioPharma is the larger company by market cap ($23.4 million vs $23.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABVC-67.80%IXHL-80.32%
+59%-15%-88%
Nov 21, 20251 yearNov 20, 2026
ABVC-96.46%IXHL-99.88%
+16%-45%-105%
Feb 28, 20225 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABVC versus IXHL key metrics
MetricABVCIXHL
Share price$0.8663$1.86
Market cap$23.37M$23.34M
1-day change-1.56%+6.90%
YTD return-59.33%-82.68%
1-year return-67.80%-80.32%
5-year return-97.29%—
EPS (TTM)$-0.20$-1.25
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$296.00K$0
Revenue growth (YoY)-41.91%-100.00%
Net income (latest FY)$-7.91M$-19.30M
Operating margin-2415.97%—
Net margin-2671.81%—
52-week high$2.87$14.91
52-week low$0.707$1.61
Distance from 52-week high-69.82%-87.53%
Analyst consensus—strong_buy
Avg. price target upside—+904.30%
Average volume81.92K91.61K
Shares outstanding26.98M12.55M
Employees1612
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ABVC has outperformed IXHL by 12.5 percentage points over the past year.
  • ABVC BioPharma grew revenue faster in its latest fiscal year (-41.91% vs -100.00%).

About ABVC BioPharma

ABVC stock →

ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients.

Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees

About Incannex Healthcare

IXHL stock →

Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder.

Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees

ABVC vs IXHL FAQ

Which is bigger, ABVC BioPharma or Incannex Healthcare?

ABVC BioPharma (ABVC) is larger, with a market capitalization of $23.37M compared with $23.34M for Incannex Healthcare (IXHL).

Which stock has performed better over the past year, ABVC or IXHL?

ABVC returned -67.80% over the past 12 months, compared with -80.32% for IXHL (price return, excluding dividends). Past performance does not predict future results.

Are ABVC BioPharma and Incannex Healthcare in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons